- Home
- Automated
- List of product information
- COSOPT OPHTHALMIC SOLUTION [SIN11643P]
COSOPT OPHTHALMIC SOLUTION [SIN11643P]
Active ingredients: COSOPT OPHTHALMIC SOLUTION
Last updated 26 October 2025
Product Info
COSOPT OPHTHALMIC SOLUTION
[SIN11643P]
Product information
Active Ingredient and Strength | DORZOLAMIDE HCL EQV. DORZOLAMIDE - 20 MG/ML |
Dosage Form | SOLUTION |
Manufacturer and Country | SANTEN PHARMACEUTICAL CO., LTD. NOTO PLANT - JAPAN |
Registration Number | SIN11643P |
Licence Holder | SANTEN PHARMACEUTICAL ASIA PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01ED51 |
III. INDICATIONS
COSOPT is indicated in the treatment of elevated IOP in patients with ocular hypertension, open-angle glaucoma, pseudoexfoliative glaucoma or other secondary open-angle glaucomas when concomitant therapy is appropriate.
IV. DOSAGE AND ADMINISTRATION
The dose is one drop of COSOPT in the affected eye(s) two times daily.
When substituting COSOPT for another ophthalmic antiglaucoma agent(s), discontinue the other agent(s) after proper dosing on one day, and start COSOPT on the next day.
If another topical ophthalmic agent is being used, COSOPT and the other agent should be administered at least ten minutes apart.
When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in an increase in local activity.
V. CONTRAINDICATIONS
COSOPT is contraindicated in patients with:
reactive airway disease, including bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease
sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pacemaker, overt cardiac failure, cardiogenic shock
severe renal impairment (CrCl<30mL/min) or hyperchloraemic acidosis
hypersensitivity to any component of this product
The above are based on the components and are not unique to the combination.